In preclinical pharmacological studies, PTEN loss has been shown to increase sensitivity to DDR-targeting agents such as poly-ADP ribose polymerase (PARP) inhibitors in a range of cancer cell lines, and in the PTEN-null colorectal cancer HCT116 xenograft model [330]. Here, PTEN is linked to cancer.